ATYR

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

aTyr Pharma, Inc.

NASDAQ | ATYR

0.82

USD

$0.00

(

0.00%

)

At Close (As of Nov 4, 2025)

$81.00M

Market Cap

-

P/E Ratio

-0.79

EPS

$7.29

52 Week High

$0.68

52 Week Low

HEALTHCARE

Sector

ATYR Chart

Recent Chart
Price Action

ATYR Technicals

Tags:

ATYR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $235K
Total Revenue $235K
Cost Of Revenue $1.5M
Costof Goods And Services Sold $1.5M
Operating Income -$68M
Selling General And Administrative $14M
Research And Development $54M
Operating Expenses $68M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.5M
Income Before Tax -$64M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$64M
Comprehensive Income Net Of Tax -
Ebit -$68M
Ebitda -$66M
Net Income -$64M

Revenue & Profitability

Earnings Performance

ATYR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $97M
Total Current Assets $82M
Cash And Cash Equivalents At Carrying Value $11M
Cash And Short Term Investments $11M
Inventory -
Current Net Receivables $1.7M
Total Non Current Assets $15M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $61M
Other Current Assets $8.1M
Other Non Current Assets -
Total Liabilities $27M
Total Current Liabilities $15M
Current Accounts Payable $4.3M
Deferred Revenue -
Current Debt -
Short Term Debt $2.5M
Total Non Current Liabilities $12M
Capital Lease Obligations $13M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $13M
Other Current Liabilities $8.1M
Other Non Current Liabilities -
Total Shareholder Equity $70M
Treasury Stock -
Retained Earnings -$532M
Common Stock $84K
Common Stock Shares Outstanding $74M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$69M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.5M
Capital Expenditures $65K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $17M
Cashflow From Financing $40M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$64M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $235K
Total Revenue $235K
Cost Of Revenue $1.5M
Costof Goods And Services Sold $1.5M
Operating Income -$68M
Selling General And Administrative $14M
Research And Development $54M
Operating Expenses $68M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.5M
Income Before Tax -$64M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$64M
Comprehensive Income Net Of Tax -
Ebit -$68M
Ebitda -$66M
Net Income -$64M

ATYR News

ATYR Profile

aTyr Pharma, Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

aTyr Pharma, Inc. is a pioneering biotherapeutics company based in San Diego, California, dedicated to the development of innovative immunological medicines. Utilizing its proprietary signaling pathway technology, aTyr focuses on creating therapeutics aimed at treating a variety of inflammatory and neuromuscular diseases. The company is actively advancing its pipeline through comprehensive research, strategic collaborations, and a commitment to addressing significant unmet medical needs. By harnessing the power of immune modulation, aTyr is poised to make impactful contributions to the biopharmaceutical industry and drive long-term value for its stakeholders.

CHR
-45.66%
$0.07
NVVE
-5.52%
$0.19
MTC
+409.86%
$1.55
ASST
+18.80%
$1.48
RIVN
+23.70%
$15.46
BYND
-4.31%
$1.33
LNAI
+45.09%
$1.21
VHAI
0.00%
$0.00
NVDA
-1.61%
$195.48
GPUS
+10.44%
$0.38
RUBI
-51.97%
$0.29
PFE
+1.29%
$24.61
YDKG
-6.48%
$0.05
SLDP
+52.09%
$8.53
SMX
+38.80%
$2.04
T
-0.36%
$24.44
PLUG
+3.82%
$2.61
TSLA
+3.71%
$460.75
PLTR
-1.60%
$187.67
AXDX
-61.36%
$0.03
F
+2.85%
$13.15
PINS
-22.92%
$25.36
DNN
-1.64%
$2.69
BITF
+6.11%
$4.07
AMD
+3.26%
$258.22
WTO
-1.40%
$0.04
SMCI
-11.11%
$42.13
INTC
+3.96%
$38.50
SNAP
-2.45%
$7.28
AAL
+6.56%
$13.47
VALE
-2.13%
$11.94
ACHR
-0.15%
$9.54
KVUE
+1.94%
$16.28
ADAP
-15.14%
$0.05
CIFR
+7.64%
$24.22
ONDS
-0.25%
$5.94
ETHD
-15.68%
$4.43
NFE
+13.99%
$1.53
SOFI
+3.06%
$30.27
TEVA
+21.56%
$24.87
RXRX
-8.08%
$5.00
DVLT
-7.83%
$1.64
MARA
+3.70%
$17.23
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
RIG
+0.38%
$3.91
BAC
-1.33%
$52.82
ADD
-25.47%
$0.05
WBD
+0.53%
$22.71
QS
+9.93%
$16.97
GRAB
-2.76%
$5.62
WULF
+2.46%
$15.38
BURU
-0.82%
$0.28
CAN
+14.43%
$1.27
EPWK
-7.75%
$0.06
FUBO
+11.27%
$4.09
SRM
+53.27%
$10.30
IREN
+12.86%
$75.19
TLRY
+3.62%
$1.28
NVO
+1.01%
$48.73
U
+17.45%
$42.13
HIMS
+3.11%
$44.12
ZDAI
+10.06%
$0.50
ALIT
-7.22%
$2.50
BMNR
+4.96%
$41.42
BTG
+1.12%
$4.04
KDLY
-11.88%
$0.78
NGD
+2.48%
$6.80
RGTI
+7.60%
$37.85
APPS
+23.72%
$7.32
BTBT
+3.81%
$3.30
NIO
+2.30%
$7.32
WLGS
-5.57%
$0.04
NOK
+0.73%
$6.86
RIOT
-2.90%
$18.71
PCG
+1.05%
$16.32
HTZ
-2.37%
$6.57
ETWO
0.00%
$3.30
HOOD
-6.98%
$136.80
RDHL
+0.88%
$1.08
NCLH
-1.25%
$18.55
AMZN
-0.36%
$248.42
BW
+38.55%
$5.18
CMG
+0.96%
$32.04
QBTS
+4.90%
$31.19
GOOGL
+2.47%
$284.42
AAPL
-0.18%
$269.53
IONZ
-7.18%
$4.14
SOUN
+2.36%
$15.48
PLTD
+1.97%
$6.47
PLTZ
+2.69%
$6.23
AG
-6.35%
$10.82
NVTS
-6.07%
$9.82
AFMD
-34.94%
$0.18
AMCR
+2.22%
$8.04
BBD
+3.16%
$3.51
ABEV
+1.04%
$2.41
CMBM
-12.03%
$2.85
MSPR
-30.73%
$0.45
HBAN
-0.65%
$15.27
CHR
-45.66%
$0.07
NVVE
-5.52%
$0.19
MTC
+409.86%
$1.55
ASST
+18.80%
$1.48
RIVN
+23.70%
$15.46
BYND
-4.31%
$1.33
LNAI
+45.09%
$1.21
VHAI
0.00%
$0.00
NVDA
-1.61%
$195.48
GPUS
+10.44%
$0.38
RUBI
-51.97%
$0.29
PFE
+1.29%
$24.61
YDKG
-6.48%
$0.05
SLDP
+52.09%
$8.53
SMX
+38.80%
$2.04
T
-0.36%
$24.44
PLUG
+3.82%
$2.61
TSLA
+3.71%
$460.75
PLTR
-1.60%
$187.67
AXDX
-61.36%
$0.03
F
+2.85%
$13.15
PINS
-22.92%
$25.36
DNN
-1.64%
$2.69
BITF
+6.11%
$4.07
AMD
+3.26%
$258.22
WTO
-1.40%
$0.04
SMCI
-11.11%
$42.13
INTC
+3.96%
$38.50
SNAP
-2.45%
$7.28
AAL
+6.56%
$13.47
VALE
-2.13%
$11.94
ACHR
-0.15%
$9.54
KVUE
+1.94%
$16.28
ADAP
-15.14%
$0.05
CIFR
+7.64%
$24.22
ONDS
-0.25%
$5.94
ETHD
-15.68%
$4.43
NFE
+13.99%
$1.53
SOFI
+3.06%
$30.27
TEVA
+21.56%
$24.87
RXRX
-8.08%
$5.00
DVLT
-7.83%
$1.64
MARA
+3.70%
$17.23
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
RIG
+0.38%
$3.91
BAC
-1.33%
$52.82
ADD
-25.47%
$0.05
WBD
+0.53%
$22.71
QS
+9.93%
$16.97
GRAB
-2.76%
$5.62
WULF
+2.46%
$15.38
BURU
-0.82%
$0.28
CAN
+14.43%
$1.27
EPWK
-7.75%
$0.06
FUBO
+11.27%
$4.09
SRM
+53.27%
$10.30
IREN
+12.86%
$75.19
TLRY
+3.62%
$1.28
NVO
+1.01%
$48.73
U
+17.45%
$42.13
HIMS
+3.11%
$44.12
ZDAI
+10.06%
$0.50
ALIT
-7.22%
$2.50
BMNR
+4.96%
$41.42
BTG
+1.12%
$4.04
KDLY
-11.88%
$0.78
NGD
+2.48%
$6.80
RGTI
+7.60%
$37.85
APPS
+23.72%
$7.32
BTBT
+3.81%
$3.30
NIO
+2.30%
$7.32
WLGS
-5.57%
$0.04
NOK
+0.73%
$6.86
RIOT
-2.90%
$18.71
PCG
+1.05%
$16.32
HTZ
-2.37%
$6.57
ETWO
0.00%
$3.30
HOOD
-6.98%
$136.80
RDHL
+0.88%
$1.08
NCLH
-1.25%
$18.55
AMZN
-0.36%
$248.42
BW
+38.55%
$5.18
CMG
+0.96%
$32.04
QBTS
+4.90%
$31.19
GOOGL
+2.47%
$284.42
AAPL
-0.18%
$269.53
IONZ
-7.18%
$4.14
SOUN
+2.36%
$15.48
PLTD
+1.97%
$6.47
PLTZ
+2.69%
$6.23
AG
-6.35%
$10.82
NVTS
-6.07%
$9.82
AFMD
-34.94%
$0.18
AMCR
+2.22%
$8.04
BBD
+3.16%
$3.51
ABEV
+1.04%
$2.41
CMBM
-12.03%
$2.85
MSPR
-30.73%
$0.45
HBAN
-0.65%
$15.27
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.